Business Wire

GA-THE-COCA-COLA-COMPANY

10.4.2024 12:01:33 CEST | Business Wire | Press release

Share
The Coca-Cola Company Celebrates Everyday Greatness with Global Program in Advance of Olympic and Paralympic Games in Paris

The Coca-Cola Company, the longest-running partner of the Olympic Games, today unveiled “Celebrate Everyday Greatness,” its theme for Paris 2024 and its global roster of athletes for Team Coca-Cola.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410031180/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Coca-Cola Paris 2024 Global Roster (Photo: Business Wire)

Celebrate Everyday Greatness is designed to champion life’s everyday moments – both big and small – that create magic that builds into something great. The Coca-Cola Company is focused on helping to make Paris 2024 the most spectacular Olympic and Paralympic Games ever, with activations across a portfolio of brands that engage fans and athletes while delivering a more sustainable experience.

“The Olympic and Paralympic Games are a prime opportunity for The Coca-Cola Company and our extensive portfolio of products to connect with fans,” said Brad Ross, VP Global Sports & Entertainment Marketing and Partnerships. “We will use this global stage to showcase how greatness in everyday moments can create real magic.”

In its role as a Worldwide Partner of the Olympic and Paralympic Games and Presenting Partner of the Paris 2024 Olympic Torch Relay, The Coca-Cola Company will refresh athletes, officials and spectators with its wide product portfolio of beverages.

Team Coca-Cola Paris 2024 Global Roster

The Olympic and Paralympic Games show that magic happens when the world comes together. Team Coca-Cola includes some of the world’s greatest athletes across different sports, countries and abilities. They represent the latest generation of outstanding stories to continue the company’s nearly century-long partnership with the Olympic Games.

“The pressure to perform can be overwhelming, especially when so many people rely on you to be your best, day-in and day-out,” said global soccer star and Team Coca-Cola athlete Debinha. “This is my third time competing in the Olympic Games. This year, I've made it a point to let those around me know how much they motivate me to be great, on and off the field, every day.”

The Coca-Cola Company Sustainability at Paris 2024

The Coca-Cola Company’s ambition is to have an Olympic and Paralympic Games without waste. The company will be providing packaging options to help minimize waste and reduce carbon emissions.

Coca-Cola will also work to collect and recycle bottles to give them new life or so that they can be refilled. This includes drink and water fountains with refill options, returnable glass bottles and bottles made with recycled materials. Coca-Cola products will be transported more sustainably during last-mile delivery. Low-carbon vehicles powered by electric, biogas or hydrogen will be used to deliver products to competition site venues and the Athletes’ Village.

Additional activations, both online and on the ground, throughout Paris 2024 will unite consumers in celebrating the magic of the Olympic and Paralympic Games. For more information on The Coca-Cola Company’s Paris 2024 activities, visit coca-colacompany.com.

Team Coca-Cola Roster:

Alberto Abarza (Chile, Swimming), Ellie Carpenter (Australia, Football), Linda Motlhalo (South Africa, Football), Alex Greenwood (England, Football), Emma Twigg (New Zealand, Rowing), Katie Bowen (New Zealand, Football), Lydia Williams (Australia, Football), Alex Morgan (U.S., Football), Florian Jouanny (France, Para Cycling), Mathilde Gros (France, Track Cycling), Alyssa Naehar (U.S., Football), Harrie Lavreysen (Netherlands, Cycling), Ramesh Budihal (India, Surfing), Athing Mu (U.S., Track & Field), Huynh Nhu (Vietnam, Football), Sarina Bolden (Philippines, Football), CJ Bott (New Zealand, Football), Ji So-Yun (South Korea, Football), Sean McColl (Canada, Sport Climbing), Daniel Smrokowski (U.S., Basketball), Kadeena Cox (U.K., Para Cycling & Para Athletics), Tyler Wright (Australia, Surfing), Debinha (Brazil, Football), Kadeisha Buchanan (Canada, Football), Wu Hai Yan (China, Football), Dimitrij Ovtcharov (Germany, Table Tennis)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410031180/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye